Abstract: The present invention generally relates to the transdermal delivery of various compounds. In some aspects, transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising a phosphodiesterase type 5 inhibitor and/or a salt thereof, and optionally, a hostile biophysical environment and/or a nitric oxide donor. In some cases, the composition may be stabilized using a combination of a stabilization polymer (such as xanthan gum, KELTROL® BT and/or KELTROL® RD), propylene glycol, and a polysorbate surfactant such as Polysorbate 20, which combination unexpectedly provides temperature stability to the composition, e.g., at elevated temperatures such as at least 40° C. (at least about 104° F.), as compared to compositions lacking one or more of these.

Abstract: In accordance with the present disclosure, there are provided formulations comprising: (a) at least one active agent; (b) an oil, and optionally a thickener therefor; (c) an organic solvent, and a thickener therefor; and (d) an oil and/or solvent soluble skin penetration enhancer; wherein: said formulation comprises <10 wt % water; and said formulation optionally forms a thixotropic thinning gel. Also provided are gels comprising oil and organic solvent, methods for preparing same and methods for the topical delivery of an active agent to a subject in need thereof.

Abstract: A composition and method for treating a subject following myocardial infarction are provided. The composition includes a non-PEGylated liposome. The method includes administering a non-PEGylated liposome to a subject in need thereof following myocardial infarction.

Abstract: The invention provides a cosmetic base having an unprecedented appearance and feeling on use, in particular a cosmetic base with a novel feeling on use that gives a fresh feeling and a unique feel as the cosmetic softly bursts and collapses, allowing water to flow out, when applied to the skin, and a skin cosmetic using the same. A cosmetic base includes (A) 0.15-0.6 mass % of sodium acrylate-grafted starch and (B) 0.25-1.35 mass % of an associative thickener having a polyoxyalkylene chain wherein the total amount of the (A) sodium acrylate-grafted starch and (B) associative thickener having a polyoxyalkylene chain compounded is 0.5-1.5 mass % and to a skin cosmetic that uses the cosmetic base.

Abstract: The disclosure relates to cosmetic compositions for treating, caring for, and/or conditioning keratinous substrates, the compositions comprising branched alkanes, dimethiconols, silicones other than dimethiconols and having a viscosity at 25° C. of greater than or equal to 200×10?6 m2/s, and non-silicone fatty compounds other than the branched alkanes. The disclosure also relates to a cosmetic treatment process using this composition, and also the use of said composition for conditioning and/or caring for keratinous substrates.

Abstract: The present invention provides antimicrobial compositions, typically aqueous compositions, for use in the inhibition and control of microorganisms, including without limitation, viruses, bacteria, fungi and yeast, on organic and inorganic surfaces. The present invention further provides methods of using such compositions for immediate and residual inhibition, including control, of such microorganisms for a period of up to 24 hours and beyond.

Abstract: Provided are surprisingly effective methods for inactivating pathogens, and for producing highly immunogenic vaccine compositions containing an inactivated pathogen rendered noninfectious by exposure to a Fenton reagent, or by exposure to a Fenton reagent or a component thereof in combination with a methisazone reagent selected from the group consisting of methisazone, methisazone analogs, functional group(s)/substructure(s) of methisazone, and combinations thereof. The methods efficiently inactivate pathogens, while substantially retaining pathogen antigenicity and/or immunogenicity, and are suitable for inactivating pathogens, or for the preparation of vaccines for a wide variety of pathogens with genomes comprising RNA or DNA, including viruses and bacteria. Also provided are highly immunogenic inactivated vaccine compositions prepared by using any of the disclosed methods, and methods for eliciting an immune response in a subject by administering such vaccine compositions.

Abstract: The present disclosure relates to a stabilized or more stable volatile compound, e.g., menthol, compositions and methods of making and using them including a mixture of a stabilizer compound of formula (I), for example, undecylenic acid methyl ester, undecylenic acid or a salt thereof and a volatile compound where the volatile compound is less susceptible to volatizing into a gas. wherein A is —(CH2)a-CH?CH—(CH 2)5-a-H where a is from 0 to 5, —(CH2)b-CH?CH—(CH 2)6-b-H where b is from 0 to 6, —(CH2)c-CH?CH—(CH 2)7-c-H where c is from 0 to 7, —(CH2)d-CH?CH—(CH 2)8-d-H where d is from 0 to 8, or —CH2)e-CH?CH—(CH 2)9-d-H where d is from 0 to 9; B is hydrogen or C1-5 alkyl; and pharmaceutically acceptable salts thereof where B is hydrogen.

Abstract: The invention relates to a method for making a tablet having a diameter, as determined by the longest enveloping circle, in the range of 1 to 5 mm and/or a weight in the range of 1 to 100 mg—comprising an active ingredient selected from the group of pharmaceutical substances and active substances for a dietary supplement or nutraceutical, comprising (a) providing a lactose agglomerate comprising lactose, and a sugar alcohol; (b) providing the active ingredient; (c) mixing the agglomerate and the active ingredient, thereby obtaining a mixture; and (d) forming the tablet by direct compression.

Abstract: A non-rinse micellar water composition; method of manufacture for a non-rinse micellar water composition; and a method of use for a micellar water composition are disclosed.

Abstract: The present invention concerns a polyelectrolyte coating comprising at least one polycationic layer consisting of at least one polycation consisting of n repetitive units having the formula (1) and at least one polyanionic layer consisting of hyaluronic acid. The polyelectrolyte coating has a biocidal activity and the invention thus further refers to the use of said polyelectrolyte coating for producing a device, in particular a bacteriostatic medical device, more particularly an implantable device, comprising said polyelectrolyte coating, and a method for preparing said device and a kit.

Abstract: Pharmaceutical compositions are described comprising (a) dimethyl fumarate, (b) a diluent selected from monosaccharides, disaccharides, starch and starch derivatives, calcium and magnesium inorganic salts, sugar alcohols, and mixtures thereof, (c) microcrystalline cellulose and (d) croscarmellose sodium, wherein the dimethyl fumarate is not covered with a gastroresistant coating. These compositions are intended for the treatment of some inflammatory autoimmune diseases or disorders.

Abstract: A respirable dry powder including acetylsalicylic acid in particles has a mass median aerodynamic diameter (MMAD) within a range of about 0.5 ?m to about 10 ?m. The respirable dry powder may contain a pharmaceutically acceptable excipient, such as a phospholipid, in an amount ranging from about 0.1% (w/w) to about 10% (w/w) of the particles.

Abstract: A synergistic antimicrobial composition having two components. The first component is 1,3-bis(hydroxymethyl)-5,5-dimethylimidazolidine-2,4-dione. The second component is a hydrogen sulfide scavenger, glyoxal.

Abstract: A trace element solution comprises at least the following metals zinc directly and/or indirectly from Zn-EDTA and/or Zn oxide; manganese directly and/or indirectly from Mn-EDTA and/or manganese carbonate; copper directly and/or indirectly from Cu-EDTA and/or copper oxide and/or copper sulphate, and/or copper carbonate; selenium derived directly and/or indirectly from Na2SeO4 and/or Na2SeO3. The metals are present in a solution of water, chlorocresol and/or benzyl alcohol, at a concentration of metals of at least 95 mg/ml. The pH of the trace element solution adjusted by means of 30% NaOH in an injectable trace element solution that is visually stable.

Abstract: Compositions and methods for an injectable liquid formulation for reducing consumption or need of a postoperative analgesic compound by a patient are presented. The pharmaceutical formulation can contain a non-opioid analgesic and a gabapentinoid, and can be administered prior to surgery to reduce postoperative pain.

Abstract: The present invention relates to an adhesive and soluble adhesive bandage or patch comprising a soluble film of natural origin with high mineral content. The soluble film comprises from 20 to 90 wt % of mineral filler and wherein the mineral filler content level is higher than the polysaccharide content level. It also relates to these bandages or patches for use in cosmetics or therapy. Also, a method of making a soluble film.

Abstract: The present disclosure provides acaricidal compounds, i.e. compounds 3c {3,6}, 3c {4,6}, 3c {3, 3}, 3c {4,3} and 3c {6,6}, that are effective in killing Varroa destructor mites while being harmless to honey bees.

Abstract: Compositions comprising select meroterpenes and a linoleic component and the use thereof in regulating the endocannabinoid system (ECS), especially in controlling and/or reducing the levels of cortisol: thereby having a stress reducing or inhibition effect.

Abstract: Sprayable compositions comprising a pyrethroid, a viscosity building agent, an emulsifier or surfactant, and an emollient are provided. The compositions have a viscosity that allows for delivery of the spray from a pressurized container such that the pyrethroid is administered in a consistent amount that uniformly covers the body of a subject. This obviates the need to rub the composition into the skin. In preferred embodiments, the pyrethroid is permethrin; the viscosity building agent is selected from the group consisting of carbomers, xanthan gum, or a combination thereof; the emulsifier or surfactant is selected from the group consisting of glyceryl mononstearate, PEG40 hydrogenated castor oil, cholesterol, steareth-10, steareth-20, and combinations thereof; and the emollient is selected from the group consisting of C12-C15 alkyl benzoates, diisopropyl adipate, silicon oil, mineral oil, or any combination thereof.